Enanta Pharmaceuticals, Inc.(ENTA)Earnings, Financials & Key RatiosEnanta Pharmaceuticals, Inc. (ENTA) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q2
the company's cash reserves of $34.9 million against a TTM net loss of approximately $81.9 million suggest a high risk of near-term dilutive financing to sustain operations.
Enanta Pharmaceuticals, Inc. (ENTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Enanta Pharmaceuticals, Inc. (ENTA) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.45vs $0.46+2.2% | $17Mvs $17M+0.8% |
| Q1 2026 | Feb 9, 2026 | $0.42vs $0.54+22.2% | $19Mvs $16M+17.0% |
| Q4 2025 | Nov 17, 2025 | $0.87vs $1.13+23.0% | $15Mvs $16M-5.3% |
| Q3 2025 | Aug 11, 2025 | $0.85vs $1.25+32.0% | $18Mvs $16M+14.7% |
Recent stock market news and headlines for Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b portion of the trial will confi.
Key metrics vs top competitors for Enanta Pharmaceuticals, Inc. (ENTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.26 | $331.07M | -3.71 | -3.42% | -125.36% | -84.63% | — | |
| $6.52 | $348.24M | -5.22 | — | — | -193.49% | — | |
| $44.01 | $2.62B | -6.18 | 48.03% | -639.84% | -34.11% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Enanta Pharmaceuticals, Inc. (ENTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Enanta Pharmaceuticals, Inc. (ENTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
Mar 26, 2026·SEC
Mar 12, 2026·SEC
Get notified when ENTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Enanta Pharmaceuticals, Inc. (ENTA) stock FAQ — growth, dividends, profitability & financials explained
Enanta Pharmaceuticals, Inc. (ENTA) reported $69.2M in revenue for fiscal year 2025. This represents a 65% increase from $41.9M in 2011.
Enanta Pharmaceuticals, Inc. (ENTA) saw revenue decline by 3.4% over the past year.
Enanta Pharmaceuticals, Inc. (ENTA) reported a net loss of $62.0M for fiscal year 2025.
Enanta Pharmaceuticals, Inc. (ENTA) has a return on equity (ROE) of -84.6%. Negative ROE indicates the company is unprofitable.
Enanta Pharmaceuticals, Inc. (ENTA) had negative free cash flow of $9.6M in fiscal year 2025, likely due to heavy capital investments.
